An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study

References

• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Shaw C. A systematic review of the literature on the prevalence of sexual impairment in women with urinary incontinence and the prevalence of urinary leakage during sexual activity. Eur Urol 2002;42:432-40
   PubMed Web of Science ®Google Scholar
• Simeonova Z, Milsom I, Kullendorff AM, et al. The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. Acta Obstet Gynecol Scand 1999;78:546-51
   PubMed Web of Science ®Google Scholar
• Milsom I, Stewart W, Thüroff J. The prevalence of overactive bladder. Am J Manag Care 2000;6(11 Suppl):S565-73
   PubMed Web of Science ®Google Scholar
• Resnick NM, Yalla SV, Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 1989;320:1-7
   PubMed Web of Science ®Google Scholar
• Geirsson G, Fall M, Lindstrom S. Subtypes of overactive bladder in old age. Age Aging 1993;22:125-31
   PubMed Web of Science ®Google Scholar
• Managing incontinence due to detrusor instability. Drug Ther Bull 2001;39:59-64
   Google Scholar
• Brown JS, Vittinghoff E, Wyman JF, et al. For the Study of Osteoporotic Fractures Research Group. Urinary incontinence: does it increase the risk for falls and factures? J Am Geriatr Soc 2000;48:721-5
   PubMed Web of Science ®Google Scholar
• Brubaker L, Shull B. EGGS for patient-centered outcomes. Int Urogynecol J 2005;16:171-3
   PubMed Web of Science ®Google Scholar
• Brubaker L, Chapple C, Coyne KS, et al. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006;68:3-8
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-64
   PubMed Web of Science ®Google Scholar
• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
   PubMed Web of Science ®Google Scholar
• Patel B, Bavendam T, Badlani G. Use of antimuscarinics in the elderly. Scientific World Journal 2009;9:459-65
   Google Scholar
• FDA Pediatric Advisory Committee. Update to the Committee: Oxybutynin Central Anticholinergic Effects. April 11, 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4295s_03_Oxybutynin%20slides_files/frame.htm
   Google Scholar
• Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2
   PubMed Web of Science ®Google Scholar
• Bemelmans BLH, Kiemeney LALM, Debruyne FMJ. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000;37:709-13
   PubMed Web of Science ®Google Scholar
• Abrams P, Freeman R, Anderström C, et al. A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10
   PubMedGoogle Scholar
• Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 1999;10:283-9
   PubMedGoogle Scholar
• Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res 1994;3:291-306
   PubMed Web of Science ®Google Scholar
• Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Neurourol Urodyn 1995;14:131-9
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Pittsburgh PA, Sathyan G, et al. Spit study to compare different formulations of oxybutynin. J Urol 1999;161:256a
   Google Scholar
• Reiz JL, Salem P, Darke AC. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. J Clin Pharmacol 2007;47:351-7
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state” a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr Res 1975;12:189-98
   PubMed Web of Science ®Google Scholar
• StatsDirect Ltd. StatsDirect statistical software. http://www.statsdirect.com. England: StatsDirect Ltd 2005; Miettinen OS, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26
   Google Scholar
• Clark CM, Sheppard L, Fillenbaum GG, et al. the CERAD Investigators. Arch Neurol 1999;56:857-62
   PubMed Web of Science ®Google Scholar
• Abrams P, Artibani W, Gajewski JB, et al. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17-28
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson K-E, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148: 565-78
   PubMed Web of Science ®Google Scholar
• McDowell BJ, Engberg S, Sereika S, et al. Effectiveness of behavioral therapy to treat incontinence in homebound older adults. J Am Geriatr Soc 1999;47:309-18
   PubMed Web of Science ®Google Scholar
• Engberg S, Sereika S, Weber E, et al. Prevalence and recognition of depressive symptoms among homebound older adults with urinary incontinence. J Geriatr Psychiatr Neurol 2001;14:130-9
   PubMed Web of Science ®Google Scholar
• Engberg S, Sereika SM, McDowell BJ, et al. Effectiveness of prompted voiding in treating urinary incontinence in cognitively impaired homebound older adults. J Wound Ostomy Continence Nurse 2002;29:252-65
   PubMedGoogle Scholar
• Schnelle JF, Traughber B, Sowell VA, et al. Prompted voiding treatment of urinary incontinence in nursing home patients. A behavior management approach for nursing home staff. J Am Geriatr Soc 1989;37:1051-7
   PubMed Web of Science ®Google Scholar
• Griffiths DJ, McCracken PN, Harrison GM, et al. Cerebral aetiology of urinary urge incontinence in elderly people. Age Ageing 1994;23:246-50
   PubMed Web of Science ®Google Scholar
• Lacker TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008;56:862-70
   PubMed Web of Science ®Google Scholar
• Corcos J, Casey R, Patrick A, et al. A double-blind randomized dose-response study comparing daily doses of 5, 10, and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2005;97:520-7
   Web of Science ®Google Scholar
• Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004;26:1026-36
   PubMed Web of Science ®Google Scholar
• Purdue Pharma. Long-term open-label extension of a randomized, double-blind parallel group comparison of the efficacy and safety of oral controlled-release oxybutynin and immediate-release oxybutynin for urinary incontinence. Report No. 018-005 Addendum; September 2004. Data on file
   Google Scholar
• Bolge SC, McDonnell DD, Chen A, et al. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin 2007;23:1903-12
   PubMed Web of Science ®Google Scholar
• Chu FM, Dmochowski RR, Lama DJ, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of the data from the OPERA trial. Am J Obstet Gynecol 2005;192:1849-55
   PubMed Web of Science ®Google Scholar
• Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one year study. Int Urol Nephrol 2002;34:43-9
   PubMedGoogle Scholar
• Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62
   PubMed Web of Science ®Google Scholar
• Brubaker L, Chapple C. Introduction. Urology 2006;68:1-2
   Web of Science ®Google Scholar